[go: up one dir, main page]

FR23C1027I2 - Régime de traitement à l'aide de nératinib pour le cancer du sein - Google Patents

Régime de traitement à l'aide de nératinib pour le cancer du sein

Info

Publication number
FR23C1027I2
FR23C1027I2 FR23C1027C FR23C1027C FR23C1027I2 FR 23C1027 I2 FR23C1027 I2 FR 23C1027I2 FR 23C1027 C FR23C1027 C FR 23C1027C FR 23C1027 C FR23C1027 C FR 23C1027C FR 23C1027 I2 FR23C1027 I2 FR 23C1027I2
Authority
FR
France
Prior art keywords
breast cancer
treatment regimen
neratinib
neratinib treatment
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1027C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42313339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of FR23C1027I1 publication Critical patent/FR23C1027I1/fr
Application granted granted Critical
Publication of FR23C1027I2 publication Critical patent/FR23C1027I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR23C1027C 2009-04-06 2023-07-24 Régime de traitement à l'aide de nératinib pour le cancer du sein Active FR23C1027I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16679609P 2009-04-06 2009-04-06
EP10722215.0A EP2416774B1 (fr) 2009-04-06 2010-03-24 Régime de traitement à l'aide de nératinib pour un cancer du sein
PCT/US2010/028448 WO2010117633A1 (fr) 2009-04-06 2010-03-24 Régime de traitement à l'aide de nératinib pour un cancer du sein

Publications (2)

Publication Number Publication Date
FR23C1027I1 FR23C1027I1 (fr) 2023-10-06
FR23C1027I2 true FR23C1027I2 (fr) 2024-07-12

Family

ID=42313339

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1027C Active FR23C1027I2 (fr) 2009-04-06 2023-07-24 Régime de traitement à l'aide de nératinib pour le cancer du sein

Country Status (31)

Country Link
US (1) US9211291B2 (fr)
EP (3) EP4218760A3 (fr)
JP (7) JP5992325B2 (fr)
KR (6) KR20220143154A (fr)
CN (3) CN103989681A (fr)
AR (1) AR076197A1 (fr)
AU (1) AU2010234968B2 (fr)
BR (1) BRPI1012699A2 (fr)
CA (1) CA2755789C (fr)
CY (2) CY1125948T1 (fr)
DK (1) DK3000467T3 (fr)
ES (2) ES2561495T3 (fr)
FI (2) FI3000467T3 (fr)
FR (1) FR23C1027I2 (fr)
HR (1) HRP20230315T1 (fr)
HU (2) HUE061640T2 (fr)
IL (4) IL264349B2 (fr)
LT (2) LT3000467T (fr)
MX (1) MX356593B (fr)
NL (1) NL301237I2 (fr)
NO (1) NO2023028I1 (fr)
NZ (1) NZ595143A (fr)
PL (1) PL3000467T3 (fr)
PT (1) PT3000467T (fr)
RU (2) RU2011139363A (fr)
SG (1) SG174382A1 (fr)
SI (1) SI3000467T1 (fr)
SM (1) SMT202300094T1 (fr)
TW (2) TW201040143A (fr)
WO (1) WO2010117633A1 (fr)
ZA (1) ZA201108118B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1848414T1 (sl) 2005-02-03 2011-08-31 Gen Hospital Corp Postopek za zdravljenje raka, odpornega na gefitinib
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
EP4218760A3 (fr) 2009-04-06 2023-08-16 Wyeth LLC Régime de traitement utilisant du nératinib pour le cancer du sein
ES2729677T3 (es) 2009-11-09 2019-11-05 Wyeth Llc Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
KR20200022187A (ko) 2018-08-22 2020-03-03 울산대학교 산학협력단 Nono의 발현 또는 활성 억제제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CA3217920A1 (fr) 2021-05-05 2022-11-10 Andreas BUCKL Inhibiteurs de ras pour le traitement du cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2024193570A1 (fr) * 2023-03-21 2024-09-26 Genequantum Healthcare (Suzhou) Co., Ltd. Associations de conjugué anticorps-médicament et de thérapie anticancéreuse et utilisation associée

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (fr) 1987-11-17 1994-03-01 Morio Fujiu Derives fluorocytidine
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
TW254946B (fr) 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU7340096A (en) 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
KR100705142B1 (ko) 1998-09-29 2007-04-06 와이어쓰 홀딩스 코포레이션 단백질 티로신 키나제 억제제로서 치환 3-시아노퀴놀린
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
BR0107456A (pt) 2000-01-07 2002-10-08 Transform Pharmaceuticals Inc Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
CA2442849A1 (fr) 2001-04-06 2002-10-17 Wyeth Combinaisons antineoplasiques telles que la rapamycine associee a la gemcitabine ou au fluorouracile
HUP0400006A2 (hu) 2001-06-01 2004-04-28 Wyeth Antineopláziás kombinációs készítmények
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
ATE370123T1 (de) 2001-11-27 2007-09-15 Wyeth Corp 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
KR20050037510A (ko) 2002-06-05 2005-04-22 세다르스-신나이 메디칼 센터 키나제 억제제를 사용하는 암 치료 방법
US20060094674A1 (en) 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005018677A2 (fr) 2003-08-01 2005-03-03 Wyeth Holdings Corporation Utilisation d'un melange d'un inhibiteur de la kinase du recepteur de facteur de croissance epidermique et d'agents cytotoxiques dans le traitement et l'inhibition de cancer
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
UA85394C2 (ru) 2003-09-15 2009-01-26 Вайет Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
US7981618B2 (en) 2003-11-05 2011-07-19 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
JP4350148B2 (ja) 2004-03-31 2009-10-21 ザ ジェネラル ホスピタル コーポレイション 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
EP1781815A2 (fr) 2004-07-23 2007-05-09 AstraZeneca AB Procede
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
JP2008515984A (ja) 2004-10-13 2008-05-15 ワイス Ｐｉ３ｋ阻害剤としての１７−ヒドロキシワートマニンの類似体
WO2006044748A2 (fr) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. Predicteurs de reponse pour medicaments specifiques de la voie erbb
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
SI1848414T1 (sl) 2005-02-03 2011-08-31 Gen Hospital Corp Postopek za zdravljenje raka, odpornega na gefitinib
WO2006081985A1 (fr) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Traitement combine par un derive de n4-(oxycarbonyl substitue)-5'-desoxy-5-fluorocytidine et un inhibiteur de l'activite kinase du recepteur du facteur de croissance epidermique
EP1859793B1 (fr) 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Nouvelle utilisation combinee d'un compose de sulfonamide dans le traitment du cancer
JP5336174B2 (ja) 2005-03-09 2013-11-06 アボット・ラボラトリーズ トラスツズマブによる治療の候補患者を確認するための診断方法
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
RU2007134908A (ru) 2005-04-14 2009-05-20 Вайет (Us) Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
WO2006116016A2 (fr) 2005-04-21 2006-11-02 The Regents Of The University Of California Determinants moleculaires de la reponse de l'inhibiteur d'egfr kinase dans le glioblastome
DK1896034T3 (da) 2005-04-28 2010-05-17 Wyeth Corp Mikroniserede tanaproget-sammensætninger og fremgangsmåder til fremstilling af disse
CA2603445A1 (fr) 2005-05-12 2006-11-16 Pfizer Inc. Polytherapie anticancereuse faisant intervenir du malate de sunitinib
AU2006249600A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CN101180269A (zh) 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
EP1904040A2 (fr) 2005-07-15 2008-04-02 Wyeth Formes pharmaceutiques orales hautement biodisponibles a liberation retardee, de o-desmethylvenlafaxine succinate
WO2007015569A1 (fr) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Procédé de prédiction de l’efficacité d’un inhibiteur de vascularisation
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1931798A1 (fr) 2005-10-05 2008-06-18 AstraZeneca UK Limited Méthode pour prédire ou surveiller la réponse d'un patient à un médicament de récepteur erbb
WO2007050495A2 (fr) 2005-10-26 2007-05-03 Children's Medical Center Corporation Methode permettant de pronostiquer une reponse a un anti-egfr
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
PE20071042A1 (es) 2005-11-04 2007-10-12 Wyeth Corp Producto farmaceutico que comprende temsirolimus y malato de sunitinib
US20090306101A1 (en) 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
PT1951274E (pt) 2005-11-24 2009-12-14 Aicuris Gmbh & Co Kg Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
CN101340895A (zh) 2005-12-22 2009-01-07 惠氏公司 包含替加环素的口服制剂
WO2007095038A2 (fr) 2006-02-09 2007-08-23 Novartis Ag Mutations et polymorphismes du gène erbb2
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
JP2009537154A (ja) 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
EP2405270B1 (fr) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. Biomarqueur IGFBP2
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
JP2010504974A (ja) 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
EP2073823A1 (fr) 2006-10-13 2009-07-01 Medigene AG Utilisation de virus oncolytiques et d'agents anti-angiogéniques dans le traitement du cancer
WO2008076257A2 (fr) 2006-12-13 2008-06-26 Schering Corporation Procédés et compositions pour traiter le cancer
WO2008076278A2 (fr) 2006-12-13 2008-06-26 Schering Corporation Procédés de traitements
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CL2008000095A1 (es) 2007-01-12 2008-05-16 Wyeth Corp Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
CA2676244C (fr) 2007-01-25 2017-01-17 Kwok-Kin Wong Utilisation d'anticorps anti-egfr dans le traitement de maladie mediee par des mutants de recepteur du facteur de croissance epidermique (egfr)
EP2124901B1 (fr) 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Préparation de comprimé ne provoquant pas de problème de pastillage
WO2008121467A2 (fr) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Polythérapie pour le traitement du cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
CA2684265A1 (fr) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection d'une proteine her-2-neu de cellules cancereuses en circulation non isolees et traitement
WO2008136838A1 (fr) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Nouveaux dérivés d'amide de cddo et leurs procédés d'utilisation
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CN101854937B (zh) 2007-09-10 2013-03-27 波士顿生物医药公司 新的stat3途径抑制剂和癌症干细胞抑制剂
WO2009042613A1 (fr) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Polythérapie pour le traitement de cancer au moyen d'inhibiteurs de la cox-2 et d'inhibiteurs doubles de l'egfr [erbb1] et de l'her-2 [erbb2]
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009055343A2 (fr) 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
WO2009061349A1 (fr) 2007-11-05 2009-05-14 Puretech Ventures Procédés, kits et compositions pour administrer des composés pharmaceutiques
JP2011505873A (ja) 2007-12-18 2011-03-03 シェーリング コーポレイション 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009105234A2 (fr) 2008-02-19 2009-08-27 Combinatorx, Incorporated Procédés et compositions pour le traitement de troubles associés à des défauts du gène ou de la protéine du régulateur de la conductance transmembranaire d'une fibrose kystique
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
US20100081632A1 (en) 2008-03-06 2010-04-01 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
EP2259797A2 (fr) 2008-03-25 2010-12-15 Schering Corporation Procédés de traitement ou de prévention de cancer colorectal
EP2279267A4 (fr) 2008-03-27 2012-01-18 Vascular Biosciences Inc Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CA2721838C (fr) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants: derives d'acide oleanolique presentant une modification du groupe amino et d'autres modifications en c-17
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
CA2721666C (fr) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants : derives d'acide oleanolique homologues c-17
JP2011519868A (ja) 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
WO2009151910A2 (fr) 2008-05-25 2009-12-17 Wyeth Produit de combinaison d'un inhibiteur de tyrosine kinase de récepteur et d'un inhibiteur d'acide gras synthase pour le traitement du cancer
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
WO2010011782A1 (fr) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Cyanoénones monocycliques et leurs procédés d'utilisation
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP2347009A4 (fr) 2008-10-14 2012-05-30 Caris Mpi Inc Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
WO2010048477A2 (fr) 2008-10-24 2010-04-29 Wyeth Llc Procede ameliore de preparation de produits couples a partir de 4-amino-3-cyanoquinoleines utilisant des intermediaires stabilises
JP2012508244A (ja) 2008-11-07 2012-04-05 エンゾン ファーマシューティカルズ，インコーポレーテッド ＥｒｂＢ−３（ＨＥＲ３）選択的併用療法
WO2010085845A1 (fr) 2009-01-28 2010-08-05 The University Of Queensland Diagnostic du cancer et/ou thérapie contre celui-ci
SG173198A1 (en) 2009-02-04 2011-09-29 Bipar Sciences Inc Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
WO2010098627A2 (fr) 2009-02-27 2010-09-02 한올바이오파마주식회사 Préparation pharmaceutique
CN102348708A (zh) 2009-03-11 2012-02-08 奥克兰联合服务有限公司 激酶抑制剂的前药形式及其在治疗中的用途
EP4218760A3 (fr) 2009-04-06 2023-08-16 Wyeth LLC Régime de traitement utilisant du nératinib pour le cancer du sein
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (fr) 2009-04-21 2010-10-28 Schering Corporation Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
EP2448563A2 (fr) 2009-07-02 2012-05-09 Wyeth LLC Formulations de comprimé de 3- cyanoquinoline et leurs utilisations
KR20110007984A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011008054A2 (fr) 2009-07-17 2011-01-20 한올바이오파마주식회사 Sel d'acide butyrique de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation, ainsi que compositions et combinaisons pharmaceutiques le contenant
WO2011025269A2 (fr) 2009-08-25 2011-03-03 한올바이오파마주식회사 Taurate de metformine, procédé de préparation correspondant, composition pharmaceutique le comprenant et formulation combinée le comprenant
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025271A2 (fr) 2009-08-25 2011-03-03 한올바이오파마주식회사 Ascorbate de metformine, procédé de préparation correspondant, composition pharmaceutique le comprenant et formulation combiné le comprenant
EP2470212A4 (fr) 2009-10-01 2013-12-04 Csl Ltd Procédé de traitement de la leucémie à chromosome philadelphie positive
ES2729677T3 (es) 2009-11-09 2019-11-05 Wyeth Llc Esferoides de fármacos recubiertos y sus usos para eliminar o reducir condiciones, como la emesis y la diarrea
ES2757882T5 (es) 2009-11-09 2023-05-10 Wyeth Llc Formulaciones de comprimidos de maleato de neratinib
SMT201800167T1 (it) 2009-11-13 2018-05-02 Amgen Inc Materiali e metodi per trattare o prevenire malattie associate a her-3
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
EP3575413A1 (fr) 2009-12-11 2019-12-04 Wyeth LLC Biomarqueurs de la voie phosphatidylinositol-3-kinase
ES2638821T3 (es) 2010-01-13 2017-10-24 Wyeth Llc Un punto de corte en la expresión de la proteína PTEN que identifica tumores con precisión y es predictivo de la respuesta a fármacos a un inhibidor pan-ErbB

Also Published As

Publication number Publication date
LT3000467T (lt) 2023-04-11
TWI557108B (zh) 2016-11-11
FR23C1027I1 (fr) 2023-10-06
CA2755789A1 (fr) 2010-10-14
US9211291B2 (en) 2015-12-15
CY2023015I1 (el) 2024-02-16
US20120071507A1 (en) 2012-03-22
TW201040143A (en) 2010-11-16
IL305394A (en) 2023-10-01
HK1167313A1 (zh) 2012-11-30
ES2561495T3 (es) 2016-02-26
EP3000467B1 (fr) 2023-03-01
CA2755789C (fr) 2016-01-19
EP4218760A3 (fr) 2023-08-16
CN102369010A (zh) 2012-03-07
KR20140036332A (ko) 2014-03-25
RU2685715C2 (ru) 2019-04-23
CY1125948T1 (el) 2024-02-16
LTPA2023520I1 (fr) 2023-08-10
HUE061640T2 (hu) 2023-07-28
IL215166A (en) 2016-09-29
CY2023015I2 (el) 2024-09-20
IL247609B (en) 2019-02-28
JP2019151671A (ja) 2019-09-12
JP2015044871A (ja) 2015-03-12
IL264349B1 (en) 2023-09-01
PT3000467T (pt) 2023-03-30
JP5992325B2 (ja) 2016-09-14
PL3000467T3 (pl) 2023-05-02
KR20190128004A (ko) 2019-11-13
IL264349B2 (en) 2024-01-01
DK3000467T3 (da) 2023-03-27
MX2011010511A (es) 2011-11-29
MX356593B (es) 2018-06-05
KR20180056796A (ko) 2018-05-29
KR20120016085A (ko) 2012-02-22
EP2416774B1 (fr) 2015-11-04
FIC20230025I1 (fi) 2023-07-19
RU2019109713A (ru) 2020-10-02
KR20160106211A (ko) 2016-09-09
CN103989681A (zh) 2014-08-20
CN105999264A (zh) 2016-10-12
BRPI1012699A2 (pt) 2016-03-22
SI3000467T1 (sl) 2023-06-30
AU2010234968B2 (en) 2015-05-14
EP2416774A1 (fr) 2012-02-15
IL215166A0 (en) 2011-12-29
JP2023076588A (ja) 2023-06-01
IL305394B2 (en) 2025-07-01
AR076197A1 (es) 2011-05-26
EP4218760A2 (fr) 2023-08-02
NZ595143A (en) 2014-01-31
TW201427954A (zh) 2014-07-16
JP2021100985A (ja) 2021-07-08
IL264349A (en) 2019-02-28
FI3000467T3 (fi) 2023-03-28
NO2023028I1 (no) 2023-07-13
NL301237I2 (nl) 2023-07-26
HRP20230315T1 (hr) 2023-05-12
HK1223027A1 (en) 2017-07-21
ZA201108118B (en) 2013-04-24
EP3000467A1 (fr) 2016-03-30
JP2016147912A (ja) 2016-08-18
KR20220143154A (ko) 2022-10-24
WO2010117633A1 (fr) 2010-10-14
RU2011139363A (ru) 2013-05-20
HUS2300023I1 (hu) 2023-08-28
JP2012522837A (ja) 2012-09-27
JP2018030891A (ja) 2018-03-01
SG174382A1 (en) 2011-11-28
RU2014130874A (ru) 2016-02-20
ES2941894T3 (es) 2023-05-26
SMT202300094T1 (it) 2023-05-12
AU2010234968A1 (en) 2011-10-13
IL305394B1 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
FR23C1027I2 (fr) Régime de traitement à l'aide de nératinib pour le cancer du sein
FR20C1061I2 (fr) Anticorps anti-cd38 pour le traitement du cancer
EP2162149A4 (fr) Vaccin pour la prevention de la rechute du cancer du sein
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EP2482849A4 (fr) Immunothérapie combinée pour le traitement du cancer
EP2478854A4 (fr) Instrument de traitement pour endoscope
EP2154971A4 (fr) Combinaison pharmaceutique synergique pour le traitement du cancer
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
EP2663367A4 (fr) Utilisation d'un agoniste de récepteur de type toll pour le traitement du cancer
EP2486134A4 (fr) Utilisation de récepteur de type toll et agoniste pour le traitement du cancer
EP2562271A4 (fr) Processus de traitement intégré pour le poinçonnage de l'acier
EP2791359A4 (fr) Diagnostics du cancer à l'aide de transcriptions non codantes
FR2912833B1 (fr) Panneau pour le traitement acoustique
EP2554175A4 (fr) Composition pour le traitement d'une partie lésée
EP2911669A4 (fr) Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
EP1869222A4 (fr) Marqueur de méthylation pour le diagnostic et le traitement des cancers
EP2385114A4 (fr) Diagnostic de traitement d'un cancer à l'aide d'un anticorps anti-tm4sf20
EP2480687A4 (fr) Méthodes et compositions pour le diagnostic et le traitement du cancer de la thyroïde
EP2744917A4 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer du sein
EP2322109A4 (fr) Instrument de traitement pour endoscope
FR2948687B1 (fr) Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
EP2698634A4 (fr) Biomarqueur pour le cancer du sein
FR2919060B1 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
EP2837381A4 (fr) Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer
EP2671524A4 (fr) Cathéter pour le traitement d'une grossesse extra-utérine, guide de cathéter et unité de cathéter pour le traitement d'une grossesse extra-utérine